Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
Background and objective Advances in molecular diagnostics have ushered in a new era for
patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular …
patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular …
[HTML][HTML] Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment
G Crisafulli - Genes, 2025 - pmc.ncbi.nlm.nih.gov
This review provides a comprehensive overview of the evolving role of minimal residual
disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for …
disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for …
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
X Li, T Liu, A Bacchiocchi, M Li, W Cheng… - EMBO Molecular …, 2024 - embopress.org
While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise
for detection of molecular residual disease (MRD), its performance is limited by WGS error …
for detection of molecular residual disease (MRD), its performance is limited by WGS error …
[HTML][HTML] Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease
M Garofoli, BA Maiorano, G Bruno, G Giordano… - European Urology …, 2024 - Elsevier
Background and objective Circulating tumor DNA (ctDNA) testing provides valuable
prognostic and predictive information for guiding therapeutic choices and monitoring …
prognostic and predictive information for guiding therapeutic choices and monitoring …
Cross-dataset pan-cancer detection: Correlating cell-free DNA fragment coverage with open chromatin sites across cell types
LR Olsen, D Odinokov, JQ Holsting, K Kondrup… - medRxiv, 2024 - medrxiv.org
The fragmentation patterns of whole genome sequenced cell-free DNA are promising
features for tumor-agnostic cancer detection. However, systematic biases challenge their …
features for tumor-agnostic cancer detection. However, systematic biases challenge their …
Low T cell diversity is associated with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire
A Kjær, N Kristjánsdóttir, RI Juul, I Nordentoft… - bioRxiv, 2024 - biorxiv.org
T cells are one of the primary effector cells in the endogenous defense against cancer, yet
the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we …
the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we …
[PDF][PDF] Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer
SV Lindskrog, L Dyrskjøt - Translational Andrology and Urology, 2024 - cdn.amegroups.cn
Correspondence to: Lars Dyrskjøt, MSc, PhD. Department of Clinical Medicine, Aarhus
University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University …
University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University …
The Potential Role of Circulating Tumor DNA as a Tool in the Management of Gastrointestinal Malignancies
Z Gottschalk, SA Cohen - Advances in Oncology, 2025 - advances-oncology.com
Gastrointestinal (GI) malignancies collectively make up 26% of new cancer diagnoses
worldwide but 35% of all cancer-related deaths [1]. With the global burden of GI …
worldwide but 35% of all cancer-related deaths [1]. With the global burden of GI …
Re: Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, et al. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor …
X Wu, X Yao, Z Chen, H Xu - European urology, 2024 - pubmed.ncbi.nlm.nih.gov
Re: Iver Nordentoft, Sia Viborg Lindskrog, Karin Birkenkamp-Demtröder, et al. Whole-genome
Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with …
Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with …
[引用][C] Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
JR Brown, GP Sonpavde, A Calaway… - European …, 2024 - pubmed.ncbi.nlm.nih.gov
Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable? Eur …
Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable? Eur …